Forest memantine neuropathic pain trial fails
Executive Summary
Forest is reviewing plans to develop diabetes agent memantine for neuropathic pain after Phase III clinical trial "failed to demonstrate a statistically significant difference versus placebo," Forest says. An earlier pivotal trial met endpoints for nocturnal pain in patients with diabetic neuropathy. Memantine is one product Forest is counting on to support long-term growth following loss of exclusivity for Celexa (1"The Pink Sheet" April 28, p. 33)...
You may also be interested in...
Forest Counting On Memantine, Benicar, To Bolster Growth Post-Celexa
Forest expects its Alzheimer's drug memantine to be approved for moderate to severe disease in the spring of 2004, Chief Operating Officer Kenneth Goodman said during a fiscal 2003 fourth quarter earnings call April 22
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.